Nkarta(NASDAQ) NKTX

Current Price$2.41

Market Cap$172.42M

Since IPO (2020)-95%

5 Year-93%

1 Year+16%

1 Month-14%

Nkarta last closing stock price
Metric	Price	Date
Last close	USD 2.41	2026-07-22

Nkarta stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-9.4%	USD 2.66	2026-07-15
1 month	-13.62%	USD 2.79	2026-06-22
3 month	-19.13%	USD 2.98	2026-04-23
Year to date	+30.27%	USD 1.85	2025-12-31
1 year	+15.87%	USD 2.08	2025-07-22
3 year	+11.57%	USD 2.16	2023-07-21
5 year	-92.5%	USD 32.14	2021-07-23
Since inception	-94.61%	USD 47.90	2020-07-10

Nkarta Financials at a Glance

Market Cap

$172.42M

Revenue (TTM)

$0.00

Net Income (TTM)

-$99.93M

EPS (TTM)

-$1.35

P/E Ratio

-1.79

Dividend

$0.00

Beta (Volatility)

1.56 (High)

Dividend

$0.00

Beta (Volatility)

1.56 (High)

Price

$2.41

Volume

740,937.313

Open

$2.53

Price

$2.41

Volume

740,937.313

Open

$2.53

Previous Close

$2.41

Daily Range

$2.40 - $2.58

52-Week Range

$1.70 - $3.72

Estimated Earnings Date

Aug 11, 2026

Dividend

$0.00

Beta (Volatility)

1.56 (High)

Price

$2.41

Volume

740,937.313

Open

$2.53

Previous Close

$2.41

Daily Range

$2.40 - $2.58

52-Week Range

$1.70 - $3.72

Estimated Earnings Date

Aug 11, 2026

NKTX News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Nkarta

Nkarta develops cell therapies to treat cancer and autoimmune diseases. Its main products aim to help patients whose immune systems cannot fight disease effectively. These therapies use engineered cells to target and destroy harmful cells in the body.

Products and Services

NKX019: Engineered natural killer (NK) cell therapy in early trials for autoimmune diseases like lupus and myositis. Represents 0% of revenue as of 2025.
NKX101: NK cell therapy for blood cancers, now deprioritized. No revenue contribution in 2025.
NK Cell Engineering Platform: Technology for expanding, modifying, and preserving NK cells for therapy development.
Manufacturing Facilities: Two sites in South San Francisco for clinical and potential commercial supply.
Research Collaborations: Joint projects with companies like CRISPR Therapeutics to develop gene-edited cell therapies.

Growth and Expansion

Formed a research partnership with CRISPR Therapeutics in 2021 to advance gene-edited NK cell therapies.
Expanded manufacturing with a second facility in South San Francisco in 2024 to support clinical and future commercial needs.
Launched Phase 1 clinical trials for NKX019 in autoimmune diseases in 2024 and 2025.
Partnered with Lupus Therapeutics in 2025 to accelerate clinical trial site activation.
Reduced workforce by 34% in March 2025 to streamline operations and cut costs.

What Makes Nkarta Stand Out

Nkarta uses an "off-the-shelf" approach, making therapies from healthy donors and storing them for quick use. Its proprietary platform allows rapid development and modification of NK cell therapies. Internal manufacturing gives the company more control over quality and supply.

Five Things You Need to Know

Revenue was $0 in 2025, unchanged from 2024 and 2023.
Net loss was $104.1 million in 2025, improving 4.3% from 2024.
Cash, cash equivalents, and investments totaled $295.1 million at December 31, 2025.
Operating expenses fell 4.8% to $122.0 million in 2025.
Headcount dropped 34% in March 2025, now at 108 employees.

Bottom Line

Nkarta remains focused on developing new cell therapies for hard-to-treat diseases. The company continues to adapt its strategy and operations as it advances clinical programs.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

108

CEO

Paul J. Hastings

Website

www.nkartatx.com

Headquarters

South San Francisco, CA 94080, US

NKTX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-30.90%

Return on Capital

-31.18%

Return on Assets

-26.86%

Earnings Yield

-55.87%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$172.42M

Shares Outstanding

71.55M

Volume

740.94K

Avg. Volume

719.80K

Financials (TTM)

Gross Profit

-$2.34M

Operating Income

-$116.31M

EBITDA

-$90.70M

Operating Cash Flow

-$87.29M

Capital Expenditure

-$1.10M

Free Cash Flow

-$88.39M

Cash & ST Invst.

$230.43M

Total Debt

$75.00M

Nkarta Performance Analysis

Nkarta annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 0	N/A
2023	2023-12-31	USD 0	N/A
2024	2024-12-31	USD 0	N/A
2025	2025-12-31	USD 0	N/A

Nkarta sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	N/A
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	N/A

Nkarta annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -2.61	-0.4%
2023	2023-12-31	USD -2.40	-8.1%
2024	2024-12-31	USD -1.60	-33.1%
2025	2025-12-31	USD -1.41	-12.2%

Nkarta sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	27.9%
Q3	2025-09-30	6.5%
Q4	2025-12-31	-27.6%
Q1	2026-03-31	N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$2.34M

N/A

Gross Margin

0.00%

N/A

Market Cap

$172.42M

N/A

Market Cap/Employee

$1.60M

N/A

Employees

108

N/A

Net Income

-$27.83M

+13.0%

EBITDA

-$25.49M

+12.6%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$230.43M

-13.2%

Total Debt

$75.00M

-5.0%

Accounts Receivable

$1.70M

-29.2%

Inventory

$0.00

N/A

Long Term Debt

$67.92M

-6.9%

Short Term Debt

$7.08M

+19.0%

Return on Assets

-26.86%

N/A

Return on Invested Capital

-32.87%

N/A

Free Cash Flow

-$28.61M

+5.0%

Operating Cash Flow

-$28.20M

+4.8%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

ALECAlector, Inc.

ALECAlector, Inc.$1.53-0.65%

MOLNMolecular Partners AG

MOLNMolecular Partners AG$3.97-3.41%

VORVor Biopharma Inc.

VORVor Biopharma Inc.$19.51-2.69%

PEPGPepGen Inc.

PEPGPepGen Inc.$1.92-9.43%

SAVACassava Sciences, Inc.

SAVACassava Sciences, Inc.$1.32+2.33%

ELTXElicio Therapeutics, Inc.

ELTXElicio Therapeutics, Inc.$3.12+1.30%

FATEFate Therapeutics, Inc.

FATEFate Therapeutics, Inc.$2.58-8.83%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

ONDSOndas

ONDSOndas$8.00+0.04%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.79-0.03%

PATHUiPath

PATHUiPath$10.70-0.11%

NOKNokia

NOKNokia$10.28-0.03%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$115.26-0.07%

FFord Motor Company

FFord Motor Company$14.42+0.01%

TET1 Energy Inc.

TET1 Energy Inc.$6.03-0.01%

Questions About NKTX

What is the current price of Nkarta?

Nkarta is trading at $2.41 per share.

What is the 52-week range for Nkarta?

Over the past 52 weeks, Nkarta has traded between $1.70 and $3.72.

How much debt does Nkarta have?

As of the most recent reporting period, Nkarta reported total debt of $75.00M.

How much cash does Nkarta have on hand?

Nkarta reported $27.36M in cash and cash equivalents in its most recent financial results.

What is Nkarta’s dividend yield?

Nkarta does not currently have a dividend yield.

Nkarta(NASDAQ) NKTX

Nkarta Financials at a Glance

NKTX News

Nkarta Posts Narrower Loss in Q2

Why Nkarta Stock Is Soaring Today

Why Shares of Nkarta Are Slumping Tuesday

2 Red-Hot Stocks That Soared More Than 60% in April

Up 131% in a Day, Is This Hot Stock a Buy?

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Nkarta

Products and Services

Growth and Expansion

What Makes Nkarta Stand Out

Five Things You Need to Know

Bottom Line

NKTX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Nkarta Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About NKTX

What is the current price of Nkarta?

What is the 52-week range for Nkarta?

How much debt does Nkarta have?

How much cash does Nkarta have on hand?

What is Nkarta’s dividend yield?

Premium Investing Services